Lilly presented Phase III data for Jaypirca (pirtobrutinib) at the European Hematology Association (EHA) 2026 annual meeting in Stockholm, demonstrating for the first time that a three-drug combination can outperform a venetoclax-containing control regimen in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
While the data are promising and gives Lilly an edge in CLL/SLL, the window for the US drugmaker to capitalize...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
